Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer

Lung cancer is the common malignant tumor with the highest mortality rate. Lung cancer patients have achieved benefits from immunotherapy, including immune checkpoint inhibitors (ICIs) therapy. Unfortunately, cancer patients acquire adaptive immune resistance, leading to poor prognosis. Tumor microe...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 14; p. 1132158
Main Authors Wang, Man, Zhu, Lijie, Yang, Xiaoxu, Li, Jiahui, Liu, Yu’e, Tang, Ying
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 15.02.2023
Subjects
immunotherapy
PD-1
PD-L1
Pharmacology
resistance
time
TME
PD-L1
time
PD-1
TME
resistance
immunotherapy
Online AccessGet full text

Cover

Abstract Lung cancer is the common malignant tumor with the highest mortality rate. Lung cancer patients have achieved benefits from immunotherapy, including immune checkpoint inhibitors (ICIs) therapy. Unfortunately, cancer patients acquire adaptive immune resistance, leading to poor prognosis. Tumor microenvironment (TME) has been demonstrated to play a critical role in participating in acquired adaptive immune resistance. TME is associated with molecular heterogeneity of immunotherapy efficacy in lung cancer. In this article, we discuss how immune cell types of TME are correlated with immunotherapy in lung cancer. Moreover, we describe the efficacy of immunotherapy in driven gene mutations in lung cancer, including KRAS, TP53, EGFR, ALK, ROS1, KEAP1, ZFHX3, PTCH1, PAK7, UBE3A, TNF-α, NOTCH, LRP1B, FBXW7, and STK11. We also emphasize that modulation of immune cell types of TME could be a promising strategy for improving adaptive immune resistance in lung cancer.
AbstractList Lung cancer is the common malignant tumor with the highest mortality rate. Lung cancer patients have achieved benefits from immunotherapy, including immune checkpoint inhibitors (ICIs) therapy. Unfortunately, cancer patients acquire adaptive immune resistance, leading to poor prognosis. Tumor microenvironment (TME) has been demonstrated to play a critical role in participating in acquired adaptive immune resistance. TME is associated with molecular heterogeneity of immunotherapy efficacy in lung cancer. In this article, we discuss how immune cell types of TME are correlated with immunotherapy in lung cancer. Moreover, we describe the efficacy of immunotherapy in driven gene mutations in lung cancer, including KRAS, TP53, EGFR, ALK, ROS1, KEAP1, ZFHX3, PTCH1, PAK7, UBE3A, TNF-α, NOTCH, LRP1B, FBXW7, and STK11. We also emphasize that modulation of immune cell types of TME could be a promising strategy for improving adaptive immune resistance in lung cancer.
Lung cancer is the common malignant tumor with the highest mortality rate. Lung cancer patients have achieved benefits from immunotherapy, including immune checkpoint inhibitors (ICIs) therapy. Unfortunately, cancer patients acquire adaptive immune resistance, leading to poor prognosis. Tumor microenvironment (TME) has been demonstrated to play a critical role in participating in acquired adaptive immune resistance. TME is associated with molecular heterogeneity of immunotherapy efficacy in lung cancer. In this article, we discuss how immune cell types of TME are correlated with immunotherapy in lung cancer. Moreover, we describe the efficacy of immunotherapy in driven gene mutations in lung cancer, including KRAS, TP53, EGFR, ALK, ROS1, KEAP1, ZFHX3, PTCH1, PAK7, UBE3A, TNF-α, NOTCH, LRP1B, FBXW7, and STK11. We also emphasize that modulation of immune cell types of TME could be a promising strategy for improving adaptive immune resistance in lung cancer.Lung cancer is the common malignant tumor with the highest mortality rate. Lung cancer patients have achieved benefits from immunotherapy, including immune checkpoint inhibitors (ICIs) therapy. Unfortunately, cancer patients acquire adaptive immune resistance, leading to poor prognosis. Tumor microenvironment (TME) has been demonstrated to play a critical role in participating in acquired adaptive immune resistance. TME is associated with molecular heterogeneity of immunotherapy efficacy in lung cancer. In this article, we discuss how immune cell types of TME are correlated with immunotherapy in lung cancer. Moreover, we describe the efficacy of immunotherapy in driven gene mutations in lung cancer, including KRAS, TP53, EGFR, ALK, ROS1, KEAP1, ZFHX3, PTCH1, PAK7, UBE3A, TNF-α, NOTCH, LRP1B, FBXW7, and STK11. We also emphasize that modulation of immune cell types of TME could be a promising strategy for improving adaptive immune resistance in lung cancer.
Author Wang, Man
Zhu, Lijie
Yang, Xiaoxu
Li, Jiahui
Liu, Yu’e
Tang, Ying
AuthorAffiliation 2 Tongji University Cancer Center , Shanghai Tenth People’s Hospital of Tongji University , School of Medicine , Tongji University , Shanghai , China
1 Department of Respiratory Medicine , The First Hospital of Jilin University , Changchun , Jilin , China
AuthorAffiliation_xml – name: 2 Tongji University Cancer Center , Shanghai Tenth People’s Hospital of Tongji University , School of Medicine , Tongji University , Shanghai , China
– name: 1 Department of Respiratory Medicine , The First Hospital of Jilin University , Changchun , Jilin , China
Author_xml – sequence: 1
  givenname: Man
  surname: Wang
  fullname: Wang, Man
– sequence: 2
  givenname: Lijie
  surname: Zhu
  fullname: Zhu, Lijie
– sequence: 3
  givenname: Xiaoxu
  surname: Yang
  fullname: Yang, Xiaoxu
– sequence: 4
  givenname: Jiahui
  surname: Li
  fullname: Li, Jiahui
– sequence: 5
  givenname: Yu’e
  surname: Liu
  fullname: Liu, Yu’e
– sequence: 6
  givenname: Ying
  surname: Tang
  fullname: Tang, Ying
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36874015$$D View this record in MEDLINE/PubMed
BookMark eNp9kk9v3CAQxa0qVZOm-QI9VBx72Q0D2OBLpSr9F2ml9pCeEcbjDakNW8Ar5dsXZzdV0kM5ABre_J40vNfViQ8eq-ot0DXnqr0cdrcmrhllfA3AGdTqRXUGTcNXrQJ28uR-Wl2kdEfL4m3LG_GqOuWNkoJCfVbFGxO3mJ3fEjdNs0dicRxJvt9hImEgeZ5CJJOzMaDfuxj8hD6THEjYY7RhQhIxuZSNt7iUf3xawWXZNkC6MdhfpkfiPBnn4mAXUXxTvRzMmPDieJ5XP798vrn6ttp8_3p99XGzsqJReQW871kvLKM4mJoOsuHSGjZwGICiEFSg4IIip1ICZTXIvjZd29dAaS2U4OfV9YHbB3Ond9FNJt7rYJx-KIS41SZmZ0fUTLUD2KajIGpBe9nJ2qBRwhQmoOgK68OBtZu7CXtbZhDN-Az6_MW7W70Ne922UqgaCuD9ERDD7xlT1pNLy6iNxzAnzaTisgUpmiJ999Trr8njpxWBOgjKp6QUcdDWZZNdWKzdqIHqJSL6ISJ6iYg-RqS0sn9aH-n_afoDTYvAAA
CitedBy_id crossref_primary_10_3390_cancers15123076
crossref_primary_10_1080_14796694_2024_2435247
crossref_primary_10_36502_2024_ASJBCCR_6380
crossref_primary_10_3389_fimmu_2025_1554256
crossref_primary_10_1038_s41388_025_03289_0
crossref_primary_10_3389_fonc_2024_1390006
crossref_primary_10_3389_fimmu_2025_1567102
Cites_doi 10.3390/cancers14194765
10.1007/s11523-017-0510-9
10.3390/ijms23062916
10.21037/jtd-21-1377
10.1042/ebc20200032
10.1016/j.cllc.2015.02.002
10.21037/tlcr-22-235
10.1155/2021/1522250
10.1111/1759-7714.13748
10.1038/s41467-021-22801-0
10.18632/oncotarget.17594
10.1016/j.cell.2020.07.017
10.1158/1078-0432.CCR-16-2554
10.1093/annonc/mdw005
10.1002/cbin.10351
10.1038/s41573-020-00091-3
10.3389/fonc.2022.912505
10.1016/j.lungcan.2022.03.019
10.1097/cad.0b013e328333d5ce
10.1016/j.lungcan.2022.05.014
10.1002/cam4.2632
10.11817/j.issn.1672-7347.2019.04.016
10.3390/curroncol29100618
10.1016/j.mcna.2022.07.007
10.1177/1758835919885540
10.20892/j.issn.2095-3941.2020.0121
10.3389/fimmu.2019.01113
10.1177/09603271211027948
10.7150/ijbs.61117
10.3892/mmr.2020.11206
10.1136/jitc-2020-001967
10.3390/ijms222312867
10.1111/1759-7714.12917
10.3389/fonc.2022.864666
10.3389/fonc.2022.945102
10.1038/s41591-021-01450-2
10.1016/j.csbj.2022.08.066
10.1007/s00262-020-02668-8
10.1016/j.semcancer.2022.06.004
10.7150/thno.52435
10.1186/s12943-021-01406-7
10.1016/j.drup.2020.100683
10.1080/14653240600845278
10.1016/j.lungcan.2022.11.014
10.1186/s12943-019-1062-7
10.5146/tjpath.2017.01398
10.1016/j.semcancer.2022.03.015
10.3322/caac.21731
10.1016/j.drup.2019.100673
10.3390/ijms23169391
10.3389/fphar.2022.875330
10.1007/s00432-020-03284-w
10.3389/fphar.2022.989461
10.21037/jtd-22-630
10.1016/j.lungcan.2019.04.005
10.1186/s12916-021-02031-3
10.1080/13543784.2018.1415324
10.1093/pcmedi/pbab027
10.1177/17534666211066064
10.1245/s10434-022-12565-2
10.5152/balkanmedj.2021.20086
10.1186/s12943-018-0789-x
10.1158/1078-0432.CCR-18-0163
10.1007/s11864-022-01022-7
10.1101/cshperspect.a031849
10.1186/s12943-022-01682-x
10.1186/s12916-022-02444-8
10.1001/jamaoncol.2016.0405
10.3389/fonc.2022.886440
10.1111/1759-7714.12652
10.1038/s41598-022-15714-5
10.3390/ijms21124325
10.1038/s41591-018-0014-x
10.7150/jca.24934
10.1038/s41568-019-0179-8
10.1158/1078-0432.CCR-19-3976
10.1002/cac2.12359
10.3389/fgene.2021.714697
10.3390/ph14090836
10.3390/cancers14246145
10.1111/sji.13087
10.2147/OTT.S312820
10.1158/0008-5472.CAN-17-1692
10.3390/biomedicines10061237
10.1016/j.biopha.2018.02.099
10.3389/fonc.2022.796832
10.1038/nrc3700
10.3390/ph14121300
10.1186/s13045-020-01025-7
10.1158/0008-5472.CAN-21-1991
10.1038/s41419-021-03410-7
10.1016/j.semcancer.2022.09.005
10.3389/fimmu.2021.709986
10.3389/fonc.2022.860313
10.1038/ni.2703
10.3389/fimmu.2021.638763
10.1186/s13045-022-01242-2
10.1016/j.lungcan.2018.07.013
10.1586/17476348.2016.1115349
10.3389/fimmu.2022.834142
10.1016/j.lungcan.2020.02.010
10.1186/s12943-019-1073-4
10.1016/j.jtho.2016.12.026
10.1111/j.1349-7006.2011.02153.x
10.1016/j.yexmp.2020.104411
10.3233/CBM-2012-00272
10.1080/1061186X.2022.2085730
10.3389/fcell.2022.773038
10.1038/s41571-021-00495-z
10.3389/fonc.2021.763027
10.3389/fonc.2022.907472
10.1016/j.bbcan.2018.04.001
10.1186/s12931-019-1137-4
10.3389/fcell.2021.795874
10.1172/jci.insight.142843
10.1186/s13045-020-01009-7
10.18632/aging.202314
10.3892/ol.2021.12855
10.1016/S1470-2045(10)70087-5
10.1016/j.ygeno.2020.12.010
10.3389/fonc.2022.911906
10.1136/jitc-2020-001536
10.1042/BSR20220892
10.20517/cdr.2021.102
10.1080/21655979.2022.2069328
10.1177/17588359211006947
10.1007/s10555-022-10039-1
10.1158/0008-5472.CAN-17-2084
10.1002/jcla.24636
10.3389/fimmu.2022.922301
10.1038/s41419-022-05057-4
10.1002/cac2.12327
10.5306/wjco.v13.i4.276
10.1080/15216549800202142
10.1007/s12032-022-01842-5
10.1186/s12943-022-01586-w
10.1158/2159-8290.CD-18-0099
10.1016/j.lungcan.2019.06.007
10.3390/ijerph17051481
10.3389/fonc.2022.962947
10.3389/fimmu.2021.799455
10.1038/s41417-019-0090-1
10.3389/fonc.2019.00254
10.1126/scisignal.aaf8223
10.2147/OTT.S290348
10.1016/j.biopha.2022.112963
10.1155/2022/9139823
10.1111/cas.13989
10.1080/14728214.2022.2113377
10.1097/CCO.0000000000000800
10.1016/j.lungcan.2018.11.025
10.3390/ijms20153821
10.3760/cma.j.cn112137-20211021-02332
10.3389/fimmu.2021.667875
10.3233/CBM-150557
10.1016/j.lungcan.2018.02.005
10.3390/cimb44020052
10.3390/cancers12082108
10.1016/j.ebiom.2020.102990
10.1016/j.ebiom.2019.02.049
10.1016/j.gendis.2020.04.001
10.3389/fonc.2021.630672
10.1186/s12929-022-00866-3
10.3389/fonc.2022.951864
10.3390/ijerph192417010
10.3322/caac.21660
10.3390/cancers14194863
10.3390/life12122104
10.3390/cancers13164037
10.3322/caac.21632
10.1002/1878-0261.12200
10.1016/j.molimm.2021.10.002
10.3389/fonc.2019.00078
10.3747/co.27.5183
10.1038/s43018-021-00195-8
10.3390/cancers13143410
10.1002/2211-5463.13501
10.3389/fonc.2022.1070243
10.1186/s43046-022-00121-8
10.1158/1078-0432.CCR-15-3101
10.1111/febs.12048
10.3389/fonc.2022.948405
10.1016/j.lungcan.2018.09.010
10.1016/j.semcancer.2020.11.004
10.1089/cell.2022.0047
10.1038/s41420-022-01157-4
10.1155/2021/3609028
10.3322/caac.21708
10.1038/srep09918
10.1016/j.canlet.2019.10.027
10.3389/fgene.2022.839957
ContentType Journal Article
Copyright Copyright © 2023 Wang, Zhu, Yang, Li, Liu and Tang.
Copyright © 2023 Wang, Zhu, Yang, Li, Liu and Tang. 2023 Wang, Zhu, Yang, Li, Liu and Tang
Copyright_xml – notice: Copyright © 2023 Wang, Zhu, Yang, Li, Liu and Tang.
– notice: Copyright © 2023 Wang, Zhu, Yang, Li, Liu and Tang. 2023 Wang, Zhu, Yang, Li, Liu and Tang
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fphar.2023.1132158
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Wang et al
EISSN 1663-9812
ExternalDocumentID oai_doaj_org_article_289f1c6b014540d7b75aea84a7d51e4b
PMC9974851
36874015
10_3389_fphar_2023_1132158
Genre Journal Article
Review
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
RNS
RPM
IAO
IEA
IHR
IHW
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c468t-13dd2d4c20efa50f7637ca2f31f10e4404e4340e3077102517d5ab9d510054843
IEDL.DBID M48
ISSN 1663-9812
IngestDate Wed Aug 27 01:21:59 EDT 2025
Thu Aug 21 18:38:37 EDT 2025
Fri Jul 11 15:20:26 EDT 2025
Thu Jan 02 22:52:29 EST 2025
Thu Apr 24 22:59:06 EDT 2025
Tue Jul 01 02:33:56 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords PD-L1
time
PD-1
TME
resistance
immunotherapy
Language English
License Copyright © 2023 Wang, Zhu, Yang, Li, Liu and Tang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c468t-13dd2d4c20efa50f7637ca2f31f10e4404e4340e3077102517d5ab9d510054843
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Lin Qi, Second Xiangya Hospital, Central South University, China
Reviewed by: Xin Cheng, Dana–Farber Cancer Institute, United States
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
Changli Wang, Tianjin Medical University Cancer Institute and Hospital, China
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fphar.2023.1132158
PMID 36874015
PQID 2783791746
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_289f1c6b014540d7b75aea84a7d51e4b
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9974851
proquest_miscellaneous_2783791746
pubmed_primary_36874015
crossref_citationtrail_10_3389_fphar_2023_1132158
crossref_primary_10_3389_fphar_2023_1132158
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-02-15
PublicationDateYYYYMMDD 2023-02-15
PublicationDate_xml – month: 02
  year: 2023
  text: 2023-02-15
  day: 15
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in pharmacology
PublicationTitleAlternate Front Pharmacol
PublicationYear 2023
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Jiang (B77) 2020; 50
Chen (B23) 2021; 11
Girard (B55) 2022; 23
Owais (B119) 2020; 12
Song (B143) 2021; 12
Dai (B31) 2021; 9
Majumder (B106) 2021; 20
Kim (B80) 2018; 27
Cardona (B16) 2019; 9
Riudavets (B133) 2022; 169
Yang (B171) 2022; 13
Zhong (B190) 2021; 12
Principe (B126) 2021; 14
Tu (B148) 2022; 7
Assoun (B5) 2019; 132
Dong (B36) 2017; 23
Tartarone (B146) 2022; 12
Bahnassy (B6) 2022; 34
Peng (B124) 2019; 18
Wood (B160) 2016; 2
Hui (B74) 2022; 13
Osielska (B118) 2018; 101
Gao (B48) 2021; 9
Yan (B169) 2022; 36
Gkountakos (B56) 2021; 13
Herreros-Pomares (B68) 2022; 30
Zhang (B182) 2022; 13
Li (B91) 2022; 86
Pang (B120) 2021; 113
Wang (B155) 2022; 9
Li (B87) 2018; 9
Nallasamy (B114) 2022; 21
Xiang (B163) 2022; 29
Li (B90) 2012; 103
Guaitoli (B59) 2021; 22
Shin (B138) 1998; 44
Ma (B105) 2015; 4
He (B67) 2016; 16
Skoulidis (B142) 2019; 19
Zhang (B183) 2022; 2022
Malhotra (B107) 2022; 14
Dowlati (B37) 2016; 27
Vathiotis (B151) 2021; 14
Yang (B172) 2021; 14
Turner (B149) 2020; 70
Yu (B174) 2022; 30
Zhang (B184) 2022; 13
Hu (B71) 2022; 8
Zhang (B177) 2013; 6
Wang (B158) 2014; 14
Wan (B152) 2021; 11
Han (B64) 2021; 14
Lin (B95) 2015; 16
Liu (B102) 2022; 102
Frazer (B43) 2022; 19
Cullis (B30) 2018; 8
Yu (B173) 2022; 12
Long (B103) 2021; 19
Rashed (B131) 2017; 1
Li (B92) 2021; 12
Minamiya (B112) 2012; 11
Gu (B57) 2013; 280
Roman (B134) 2018; 17
Adderley (B3) 2019; 41
Bredin (B12) 2022; 41
Ferrer (B42) 2018; 124
Pao (B121) 2011; 12
Bote (B10) 2022; 27
Niu (B116) 2021; 22
Xie (B165) 2022; 83
Wang (B157) 2020; 22
Gamell (B47) 2017; 10
Martin (B108) 2022; 12
Kohli (B82) 2018; 78
Cognigni (B29) 2022; 14
Siegel (B139) 2022; 72
Xu (B166) 2023; 13
Principe (B127) 2022; 12
Uras (B150) 2020; 21
Kim (B81) 2017; 8
Ricciuti (B132) 2016; 10
Wu (B161) 2021; 12
Sakai (B135) 2019; 127
Zhang (B181) 2022; 21
Biton (B9) 2018; 24
Liu (B100) 2022; 10
Garcia-Robledo (B51) 2022; 16
Han (B65) 2014; 38
Caliman (B14) 2022; 175
Ahluwalia (B4) 2021; 13
Serra (B136) 2018; 118
Eulberg (B40) 2022; 12
Chen (B22) 2021; 12
Castaneda-Gonzalez (B17) 2022; 11
Binnewies (B8) 2018; 24
Hu (B72) 2021; 2021
Qin (B128) 2022; 23
Hong (B69) 2022; 82
Sun (B144) 2020; 60
Sigafoos (B140) 2021; 13
Xiao (B164) 2018; 12
Zhou (B193) 2019; 9
Guo (B62) 2022; 12
Sung (B145) 2021; 71
Li (B85) 2022; 13
Hsu (B70) 2019; 20
Zhang (B179) 2021; 94
Luo (B104) 2021; 4
Ackermann (B2) 2019; 134
Zhao (B186) 2022; 20
Zhou (B191) 2022; 20
Jiang (B76) 2021; 140
Cheng (B26) 2022; 14
Ghafouri-Fard (B54) 2020; 114
Hao (B66) 2022; 12
Olmedo (B117) 2022; 13
Zhao (B188) 2021; 12
Fu (B44) 2020; 13
Choi (B27) 2022; 106
Mengoli (B110) 2018; 110
Liu (B97) 2022; 42
Miller (B111) 2022; 72
Chen (B20) 2019; 10
Zhang (B178) 2021; 70
Peng (B123) 2022; 34
Yan (B170) 2006; 8
Quan (B129) 2020; 27
Cao (B15) 2022; 24
Chen (B21) 2020; 142
Chen (B25) 2022; 12
Jin (B78) 2020; 17
Lee (B83) 2019; 10
Gajewski (B46) 2013; 14
Dias Carvalho (B35) 2018; 78
Zhao (B187) 2022; 12
Liu (B99) 2022; 86
Bourbonne (B11) 2022; 10
Jiang (B75) 2021; 20
Gainor (B45) 2016; 22
Liu (B101) 2018; 125
Wu (B162) 2022; 15
Weng (B159) 2021; 11
Gu (B58) 2021; 40
Jin (B79) 2021; 2021
Faraj (B41) 2022; 39
Li (B88) 2019; 8
Entezari (B39) 2022; 150
Abdayem (B1) 2022; 20
Ekin (B38) 2021; 38
Yan (B168) 2020; 49
Li (B84) 2022; 167
Di Nicolantonio (B34) 2021; 18
Lin (B93) 2019; 18
Mussafi (B113) 2022; 12
Lin (B94) 2021; 12
Guan (B60) 2022; 86
Li (B86) 2022; 5
Ni (B115) 2021; 14
Zhou (B194) 2020; 146
Ceddia (B19) 2022; 23
Gao (B49) 2018; 1869
Yan (B167) 2021; 65
Passaro (B122) 2021; 2
Zeng (B176) 2022; 13
Genova (B53) 2021; 12
Barbirou (B7) 2022; 44
Huang (B73) 2022; 13
Maynard (B109) 2020; 182
Sforza (B137) 2022; 14
Wang (B154) 2021; 27
Peng (B125) 2019; 44
Bylicki (B13) 2017; 12
Guo (B61) 2020; 17
Li (B89) 2010; 21
Desage (B33) 2022; 12
Liu (B96) 2020; 470
Guo (B63) 2019; 110
Cinausero (B28) 2019; 11
Skoulidis (B141) 2018; 8
Gemelli (B52) 2022; 12
Chen (B24) 2022; 42
Dawe (B32) 2020; 27
Gao (B50) 2020; 13
Wang (B153) 2018; 9
Zhou (B192) 2022; 12
Rangachari (B130) 2017; 12
Tiwari (B147) 2022; 29
Liu (B98) 2022; 12
Wang (B156) 2022
Zhang (B185) 2019; 20
Catalano (B18) 2022; 14
Zheng (B189) 2021; 17
Yue (B175) 2021; 9
Zhang (B180) 2020; 26
References_xml – volume: 14
  start-page: 4765
  year: 2022
  ident: B29
  article-title: The landscape of ALK-rearranged non-small cell lung cancer: A comprehensive review of clinicopathologic, genomic characteristics, and therapeutic perspectives
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers14194765
– volume: 12
  start-page: 563
  year: 2017
  ident: B13
  article-title: Targeting the PD-1/PD-L1 immune checkpoint in EGFR-mutated or ALK-translocated non-small-cell lung cancer
  publication-title: Target Oncol.
  doi: 10.1007/s11523-017-0510-9
– volume: 23
  start-page: 2916
  year: 2022
  ident: B128
  article-title: The challenge and opportunity of NTRK inhibitors in non-small cell lung cancer
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms23062916
– volume: 14
  start-page: 1772
  year: 2022
  ident: B107
  article-title: Clinical outcomes and immune phenotypes associated with STK11 co-occurring mutations in non-small cell lung cancer
  publication-title: J. Thorac. Dis.
  doi: 10.21037/jtd-21-1377
– volume: 65
  start-page: 625
  year: 2021
  ident: B167
  article-title: Non-coding RNA in cancer
  publication-title: Essays Biochem.
  doi: 10.1042/ebc20200032
– volume: 16
  start-page: e25
  year: 2015
  ident: B95
  article-title: Programmed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinoma
  publication-title: Clin. Lung Cancer
  doi: 10.1016/j.cllc.2015.02.002
– volume: 11
  start-page: 2148
  year: 2022
  ident: B17
  article-title: Multiple mutations in the EGFR gene in lung cancer: A systematic review
  publication-title: Transl. Lung Cancer Res.
  doi: 10.21037/tlcr-22-235
– volume: 2021
  start-page: 1522250
  year: 2021
  ident: B72
  article-title: Correlation between LRP1B mutations and tumor mutation burden in gastric cancer
  publication-title: Comput. Math. Methods Med.
  doi: 10.1155/2021/1522250
– volume: 12
  start-page: 218
  year: 2021
  ident: B22
  article-title: Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions
  publication-title: Thorac. Cancer
  doi: 10.1111/1759-7714.13748
– volume: 12
  start-page: 2540
  year: 2021
  ident: B161
  article-title: Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-22801-0
– volume: 8
  start-page: 48248
  year: 2017
  ident: B81
  article-title: Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.17594
– volume: 182
  start-page: 1232
  year: 2020
  ident: B109
  article-title: Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing
  publication-title: Cell
  doi: 10.1016/j.cell.2020.07.017
– volume: 23
  start-page: 3012
  year: 2017
  ident: B36
  article-title: Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-16-2554
– volume: 27
  start-page: 642
  year: 2016
  ident: B37
  article-title: Clinical correlation of extensive-stage small-cell lung cancer genomics
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdw005
– volume: 38
  start-page: 1394
  year: 2014
  ident: B65
  article-title: p21-activated kinase 7 is an oncogene in human osteosarcoma
  publication-title: Cell Biol. Int.
  doi: 10.1002/cbin.10351
– volume: 20
  start-page: 125
  year: 2021
  ident: B106
  article-title: Targeting Notch in oncology: The path forward
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-020-00091-3
– volume: 12
  start-page: 912505
  year: 2022
  ident: B187
  article-title: Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.912505
– volume: 167
  start-page: 25
  year: 2022
  ident: B84
  article-title: Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2022.03.019
– volume: 21
  start-page: 243
  year: 2010
  ident: B89
  article-title: Safety evaluation and pharmacokinetics of a novel human tumor necrosis factor-alpha exhibited a higher antitumor activity and a lower systemic toxicity
  publication-title: Anticancer Drugs
  doi: 10.1097/cad.0b013e328333d5ce
– volume: 169
  start-page: 102
  year: 2022
  ident: B133
  article-title: Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2022.05.014
– volume: 8
  start-page: 7669
  year: 2019
  ident: B88
  article-title: Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy
  publication-title: Cancer Med.
  doi: 10.1002/cam4.2632
– volume: 44
  start-page: 444
  year: 2019
  ident: B125
  article-title: Research progress in the role of FBXW7 in drug resistance against non-small cell lung cancer
  publication-title: Zhong Nan Da Xue Xue Bao Yi Xue Ban.
  doi: 10.11817/j.issn.1672-7347.2019.04.016
– volume: 29
  start-page: 7816
  year: 2022
  ident: B163
  article-title: Therapeutic advances of rare ALK fusions in non-small cell lung cancer
  publication-title: Curr. Oncol.
  doi: 10.3390/curroncol29100618
– volume: 106
  start-page: 1041
  year: 2022
  ident: B27
  article-title: Lung cancer screening
  publication-title: Med. Clin. North Am.
  doi: 10.1016/j.mcna.2022.07.007
– volume: 11
  start-page: 1758835919885540
  year: 2019
  ident: B28
  article-title: KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
  publication-title: Ther. Adv. Med. Oncol.
  doi: 10.1177/1758835919885540
– volume: 17
  start-page: 768
  year: 2020
  ident: B78
  article-title: Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
  publication-title: Cancer Biol. Med.
  doi: 10.20892/j.issn.2095-3941.2020.0121
– volume: 10
  start-page: 1113
  year: 2019
  ident: B20
  article-title: Association of LRP1B mutation with tumor mutation burden and outcomes in melanoma and non-small cell lung cancer patients treated with immune check-point blockades
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.01113
– volume: 40
  start-page: 2202
  year: 2021
  ident: B58
  article-title: Inhibiting p21-activated kinase (PAK7) enhances radiosensitivity in hepatocellular carcinoma
  publication-title: Hum. Exp. Toxicol.
  doi: 10.1177/09603271211027948
– volume: 17
  start-page: 3024
  year: 2021
  ident: B189
  article-title: UBE3A activates the NOTCH pathway and promotes esophageal cancer progression by degradation of ZNF185
  publication-title: Int. J. Biol. Sci.
  doi: 10.7150/ijbs.61117
– volume: 22
  start-page: 1362
  year: 2020
  ident: B157
  article-title: Bioinformatic analysis of the potential molecular mechanism of PAK7 expression in glioblastoma
  publication-title: Mol. Med. Rep.
  doi: 10.3892/mmr.2020.11206
– volume: 9
  start-page: e001967
  year: 2021
  ident: B175
  article-title: Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2020-001967
– volume: 22
  start-page: 12867
  year: 2021
  ident: B59
  article-title: Deepening the knowledge of ROS1 rearrangements in non-small cell lung cancer: Diagnosis, treatment, resistance and concomitant alterations
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms222312867
– volume: 10
  start-page: 103
  year: 2019
  ident: B83
  article-title: PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
  publication-title: Thorac. Cancer
  doi: 10.1111/1759-7714.12917
– volume: 12
  start-page: 864666
  year: 2022
  ident: B98
  article-title: NTRK fusion in non-small cell lung cancer: Diagnosis, therapy, and TRK inhibitor resistance
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.864666
– volume: 12
  start-page: 945102
  year: 2022
  ident: B62
  article-title: Current treatments for non-small cell lung cancer
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.945102
– volume: 27
  start-page: 1345
  year: 2021
  ident: B154
  article-title: Toward personalized treatment approaches for non-small-cell lung cancer
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01450-2
– volume: 20
  start-page: 5001
  year: 2022
  ident: B186
  article-title: Recognition of immune-related tumor antigens and immune subtypes for mRNA vaccine development in lung adenocarcinoma
  publication-title: Comput. Struct. Biotechnol. J.
  doi: 10.1016/j.csbj.2022.08.066
– volume: 70
  start-page: 137
  year: 2021
  ident: B178
  article-title: ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-020-02668-8
– volume: 86
  start-page: 259
  year: 2022
  ident: B99
  article-title: Targeting matrix metalloproteinases by E3 ubiquitin ligases as a way to regulate the tumor microenvironment for cancer therapy
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2022.06.004
– volume: 11
  start-page: 3392
  year: 2021
  ident: B23
  article-title: ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation
  publication-title: Theranostics
  doi: 10.7150/thno.52435
– volume: 20
  start-page: 116
  year: 2021
  ident: B75
  article-title: The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-021-01406-7
– volume: 50
  start-page: 100683
  year: 2020
  ident: B77
  article-title: Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2020.100683
– volume: 6
  start-page: 1734
  year: 2013
  ident: B177
  article-title: Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines
  publication-title: Int. J. Clin. Exp. Pathol.
– volume: 8
  start-page: 415
  year: 2006
  ident: B170
  article-title: A mutated human tumor necrosis factor-alpha improves the therapeutic index in vitro and in vivo
  publication-title: Cytotherapy
  doi: 10.1080/14653240600845278
– volume: 175
  start-page: 88
  year: 2022
  ident: B14
  article-title: Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2022.11.014
– volume: 18
  start-page: 139
  year: 2019
  ident: B93
  article-title: Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-019-1062-7
– volume: 1
  start-page: 211
  year: 2017
  ident: B131
  article-title: Prognostic significance of programmed cell death ligand 1 (PD-L1), CD8+ tumor-infiltrating lymphocytes and p53 in non-small cell lung cancer: An immunohistochemical study
  publication-title: Turk Patoloji Derg.
  doi: 10.5146/tjpath.2017.01398
– volume: 86
  start-page: 346
  year: 2022
  ident: B60
  article-title: Evolution of small cell lung cancer tumor mutation: From molecular mechanisms to novel viewpoints
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2022.03.015
– volume: 72
  start-page: 409
  year: 2022
  ident: B111
  article-title: Cancer treatment and survivorship statistics
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21731
– volume: 49
  start-page: 100673
  year: 2020
  ident: B168
  article-title: Emerging roles of F-box proteins in cancer drug resistance
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2019.100673
– volume: 23
  start-page: 9391
  year: 2022
  ident: B19
  article-title: KRAS-mutant non-small-cell lung cancer: From past efforts to future challenges
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms23169391
– volume: 13
  start-page: 875330
  year: 2022
  ident: B85
  article-title: Targeting mutant kirsten rat sarcoma viral oncogene homolog in non-small cell lung cancer: Current difficulties, integrative treatments and future perspectives
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2022.875330
– volume: 146
  start-page: 2277
  year: 2020
  ident: B194
  article-title: Mutational profiling of lung adenocarcinoma in China detected by next-generation sequencing
  publication-title: J. Cancer Res. Clin. Oncol.
  doi: 10.1007/s00432-020-03284-w
– volume: 13
  start-page: 989461
  year: 2022
  ident: B171
  article-title: Current status of immunotherapy for non-small cell lung cancer
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2022.989461
– volume: 14
  start-page: 2224
  year: 2022
  ident: B26
  article-title: Prognostic significance of PD-L1 expression and CD8(+) TILs density for disease-free survival in surgically resected lung squamous cell carcinoma: A retrospective study
  publication-title: J. Thorac. Dis.
  doi: 10.21037/jtd-22-630
– volume: 132
  start-page: 65
  year: 2019
  ident: B5
  article-title: Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2019.04.005
– volume: 19
  start-page: 154
  year: 2021
  ident: B103
  article-title: Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy
  publication-title: BMC Med.
  doi: 10.1186/s12916-021-02031-3
– volume: 27
  start-page: 17
  year: 2018
  ident: B80
  article-title: MEK inhibitors under development for treatment of non-small-cell lung cancer
  publication-title: Expert Opin. Investig. Drugs
  doi: 10.1080/13543784.2018.1415324
– volume: 4
  start-page: 258
  year: 2021
  ident: B104
  article-title: Immunotherapy in non-small cell lung cancer: Rationale, recent advances and future perspectives
  publication-title: Precis. Clin. Med.
  doi: 10.1093/pcmedi/pbab027
– volume: 16
  start-page: 17534666211066064
  year: 2022
  ident: B51
  article-title: KRAS and MET in non-small-cell lung cancer: Two of the new kids on the 'drivers' block
  publication-title: Ther. Adv. Respir. Dis.
  doi: 10.1177/17534666211066064
– volume: 30
  start-page: 1225
  year: 2022
  ident: B68
  article-title: A sonic hedgehog pathway score to predict the outcome of resected non-small cell lung cancer patients
  publication-title: Ann. Surg. Oncol.
  doi: 10.1245/s10434-022-12565-2
– volume: 38
  start-page: 287
  year: 2021
  ident: B38
  article-title: Comparison of PD-L1, EGFR, ALK, and ROS1 status between surgical samples and cytological samples in non-small cell lung carcinoma
  publication-title: Balk. Med. J.
  doi: 10.5152/balkanmedj.2021.20086
– volume: 17
  start-page: 33
  year: 2018
  ident: B134
  article-title: KRAS oncogene in non-small cell lung cancer: Clinical perspectives on the treatment of an old target
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-018-0789-x
– volume: 24
  start-page: 5710
  year: 2018
  ident: B9
  article-title: TP53, STK11, and EGFR mutations predict tumor immune profile and the response to anti-PD-1 in lung adenocarcinoma
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-0163
– volume: 23
  start-page: 1626
  year: 2022
  ident: B55
  article-title: New strategies and novel combinations in EGFR TKI-resistant non-small cell lung cancer
  publication-title: Curr. Treat. Options Oncol.
  doi: 10.1007/s11864-022-01022-7
– volume: 8
  start-page: a031849
  year: 2018
  ident: B30
  article-title: Kras and tumor immunity: Friend or foe?
  publication-title: Cold Spring Harb. Perspect. Med.
  doi: 10.1101/cshperspect.a031849
– volume: 21
  start-page: 225
  year: 2022
  ident: B114
  article-title: Tumor microenvironment enriches the stemness features: The architectural event of therapy resistance and metastasis
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-022-01682-x
– volume: 20
  start-page: 256
  year: 2022
  ident: B191
  article-title: Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer
  publication-title: BMC Med.
  doi: 10.1186/s12916-022-02444-8
– volume: 2
  start-page: 805
  year: 2016
  ident: B160
  article-title: Prognostic and predictive value in KRAS in non-small-cell lung cancer: A review
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2016.0405
– volume: 12
  start-page: 886440
  year: 2022
  ident: B52
  article-title: Overcoming resistance to checkpoint inhibitors: Natural killer cells in non-small cell lung cancer
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.886440
– volume: 9
  start-page: 761
  year: 2018
  ident: B153
  article-title: Role of long non-coding RNA in drug resistance in non-small cell lung cancer
  publication-title: Thorac. Cancer
  doi: 10.1111/1759-7714.12652
– volume: 12
  start-page: 11490
  year: 2022
  ident: B127
  article-title: Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-022-15714-5
– volume: 21
  start-page: 4325
  year: 2020
  ident: B150
  article-title: Targeting KRAS mutant non-small-cell lung cancer: Past, present and future
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms21124325
– volume: 24
  start-page: 541
  year: 2018
  ident: B8
  article-title: Understanding the tumor immune microenvironment (TIME) for effective therapy
  publication-title: Nat. Med.
  doi: 10.1038/s41591-018-0014-x
– volume: 9
  start-page: 1821
  year: 2018
  ident: B87
  article-title: P21-activated kinase 7 (PAK7) interacts with and activates Wnt/β-catenin signaling pathway in breast cancer
  publication-title: J. Cancer
  doi: 10.7150/jca.24934
– volume: 19
  start-page: 495
  year: 2019
  ident: B142
  article-title: Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/s41568-019-0179-8
– volume: 26
  start-page: 3649
  year: 2020
  ident: B180
  article-title: Identification of deleterious NOTCH mutation as novel predictor to efficacious immunotherapy in NSCLC
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-19-3976
– volume: 42
  start-page: 937
  year: 2022
  ident: B24
  article-title: Non-small cell lung cancer in China
  publication-title: Cancer Commun. (Lond)
  doi: 10.1002/cac2.12359
– volume: 12
  start-page: 714697
  year: 2021
  ident: B188
  article-title: Relationships of N6-methyladenosine-related long non-coding RNAs with tumor immune microenvironment and clinical prognosis in lung adenocarcinoma
  publication-title: Front. Genet.
  doi: 10.3389/fgene.2021.714697
– volume: 14
  start-page: 836
  year: 2021
  ident: B126
  article-title: LRP1B: A giant lost in cancer translation
  publication-title: Pharm. (Basel)
  doi: 10.3390/ph14090836
– volume: 14
  start-page: 6145
  year: 2022
  ident: B18
  article-title: Lung cancer immunotherapy: Beyond common immune checkpoints inhibitors
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers14246145
– volume: 94
  start-page: e13087
  year: 2021
  ident: B179
  article-title: Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors
  publication-title: Scand. J. Immunol.
  doi: 10.1111/sji.13087
– volume: 14
  start-page: 4087
  year: 2021
  ident: B115
  article-title: Progress in treatment of non-small cell lung cancer harboring HER2 aberrations
  publication-title: Onco Targets Ther.
  doi: 10.2147/OTT.S312820
– volume: 78
  start-page: 645
  year: 2018
  ident: B82
  article-title: SIRT6 is a target of regulation by UBE3A that contributes to liver tumorigenesis in an ANXA2-dependent manner
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-17-1692
– volume: 10
  start-page: 1237
  year: 2022
  ident: B11
  article-title: Multi-omics approaches for the prediction of clinical endpoints after immunotherapy in non-small cell lung cancer: A comprehensive review
  publication-title: Biomedicines
  doi: 10.3390/biomedicines10061237
– volume: 101
  start-page: 322
  year: 2018
  ident: B118
  article-title: Long non-coding RNA as potential biomarkers in non-small-cell lung cancer: What do we know so far?
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2018.02.099
– volume: 12
  start-page: 796832
  year: 2022
  ident: B33
  article-title: Targeting KRAS mutant in non-small cell lung cancer: Novel insights into therapeutic strategies
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.796832
– volume: 14
  start-page: 233
  year: 2014
  ident: B158
  article-title: Roles of F-box proteins in cancer
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3700
– volume: 14
  start-page: 1300
  year: 2021
  ident: B151
  article-title: HER2 aberrations in non-small cell lung cancer: From pathophysiology to targeted therapy
  publication-title: Pharm. (Basel)
  doi: 10.3390/ph14121300
– volume: 14
  start-page: 1
  year: 2021
  ident: B64
  article-title: MEK inhibitors for the treatment of non-small cell lung cancer
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-020-01025-7
– volume: 82
  start-page: 248
  year: 2022
  ident: B69
  article-title: Plasticity in the absence of NOTCH uncovers a RUNX2-dependent pathway in small cell lung cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-21-1991
– volume: 12
  start-page: 106
  year: 2021
  ident: B143
  article-title: Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis
  publication-title: Cell Death Dis.
  doi: 10.1038/s41419-021-03410-7
– volume: 86
  start-page: 117
  year: 2022
  ident: B91
  article-title: Unraveling tumor microenvironment of small-cell lung cancer: Implications for immunotherapy
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2022.09.005
– volume: 12
  start-page: 709986
  year: 2021
  ident: B190
  article-title: Dissecting tumor antigens and immune subtypes of glioma to develop mRNA vaccine
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.709986
– volume: 12
  start-page: 860313
  year: 2022
  ident: B173
  article-title: HER2-Altered non-small cell lung cancer: Biology, clinicopathologic features, and emerging therapies
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.860313
– volume: 14
  start-page: 1014
  year: 2013
  ident: B46
  article-title: Innate and adaptive immune cells in the tumor microenvironment
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2703
– volume: 12
  start-page: 638763
  year: 2021
  ident: B92
  article-title: The impact of NOTCH pathway alteration on tumor microenvironment and clinical survival of immune checkpoint inhibitors in NSCLC
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.638763
– volume: 15
  start-page: 24
  year: 2022
  ident: B162
  article-title: Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-022-01242-2
– volume: 124
  start-page: 53
  year: 2018
  ident: B42
  article-title: KRAS-Mutant non-small cell lung cancer: From biology to therapy
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2018.07.013
– volume: 10
  start-page: 53
  year: 2016
  ident: B132
  article-title: Targeting the KRAS variant for treatment of non-small cell lung cancer: Potential therapeutic applications
  publication-title: Expert Rev. Respir. Med.
  doi: 10.1586/17476348.2016.1115349
– volume: 13
  start-page: 834142
  year: 2022
  ident: B176
  article-title: The predictive value of PAK7 mutation for immune checkpoint inhibitors therapy in non-small cell cancer
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2022.834142
– volume: 142
  start-page: 98
  year: 2020
  ident: B21
  article-title: PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2020.02.010
– volume: 18
  start-page: 165
  year: 2019
  ident: B124
  article-title: EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-019-1073-4
– volume: 12
  start-page: 878
  year: 2017
  ident: B130
  article-title: Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2016.12.026
– volume: 103
  start-page: 288
  year: 2012
  ident: B90
  article-title: Phase II multicenter, randomized, double-blind study of recombinant mutated human tumor necrosis factor-alpha in combination with chemotherapies in cancer patients
  publication-title: Cancer Sci.
  doi: 10.1111/j.1349-7006.2011.02153.x
– volume: 114
  start-page: 104411
  year: 2020
  ident: B54
  article-title: Non-coding RNA profile in lung cancer
  publication-title: Exp. Mol. Pathol.
  doi: 10.1016/j.yexmp.2020.104411
– volume: 11
  start-page: 139
  year: 2012
  ident: B112
  article-title: Suppression of Zinc Finger Homeobox 3 expression in tumor cells decreases the survival rate among non-small cell lung cancer patients
  publication-title: Cancer Biomark.
  doi: 10.3233/CBM-2012-00272
– volume: 30
  start-page: 845
  year: 2022
  ident: B174
  article-title: ROS1-positive non-small cell lung cancer (NSCLC): Biology, diagnostics, therapeutics and resistance
  publication-title: J. Drug Target
  doi: 10.1080/1061186X.2022.2085730
– volume: 10
  start-page: 773038
  year: 2022
  ident: B100
  article-title: The roles of noncoding RNAs in the development of osteosarcoma stem cells and potential therapeutic targets
  publication-title: Front. Cell Dev. Biol.
  doi: 10.3389/fcell.2022.773038
– volume: 18
  start-page: 506
  year: 2021
  ident: B34
  article-title: Precision oncology in metastatic colorectal cancer - from biology to medicine
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-021-00495-z
– volume: 11
  start-page: 763027
  year: 2021
  ident: B159
  article-title: Identification of a N6-methyladenosine (m6A)-Related lncRNA signature for predicting the prognosis and immune landscape of lung squamous cell carcinoma
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2021.763027
– volume: 12
  start-page: 907472
  year: 2022
  ident: B25
  article-title: Long intergenic noncoding RNA00265 enhances cell viability and metastasis via targeting miR-485-5p/USP22 Axis in osteosarcoma
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.907472
– volume: 1869
  start-page: 278
  year: 2018
  ident: B49
  article-title: ILT4 functions as a potential checkpoint molecule for tumor immunotherapy
  publication-title: Biochim. Biophys. Acta Rev. Cancer
  doi: 10.1016/j.bbcan.2018.04.001
– volume: 20
  start-page: 164
  year: 2019
  ident: B185
  article-title: The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer
  publication-title: Respir. Res.
  doi: 10.1186/s12931-019-1137-4
– volume: 9
  start-page: 795874
  year: 2021
  ident: B31
  article-title: Long non-coding RNAs in lung cancer: The role in tumor microenvironment
  publication-title: Front. Cell Dev. Biol.
  doi: 10.3389/fcell.2021.795874
– volume: 7
  start-page: e142843
  year: 2022
  ident: B148
  article-title: Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.142843
– volume: 13
  start-page: 169
  year: 2020
  ident: B44
  article-title: Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-020-01009-7
– volume: 13
  start-page: 2668
  year: 2020
  ident: B50
  article-title: Notch-1 promotes the malignant progression of osteosarcoma through the activation of cell division cycle 20
  publication-title: Aging (Albany NY)
  doi: 10.18632/aging.202314
– volume: 22
  start-page: 594
  year: 2021
  ident: B116
  article-title: Next-generation sequencing-based identification of EGFR and NOTCH2 complementary mutations in non-small cell lung cancer
  publication-title: Oncol. Lett.
  doi: 10.3892/ol.2021.12855
– volume: 12
  start-page: 175
  year: 2011
  ident: B121
  article-title: New driver mutations in non-small-cell lung cancer
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(10)70087-5
– volume: 113
  start-page: 291
  year: 2021
  ident: B120
  article-title: Long non-coding RNA C5orf64 is a potential indicator for tumor microenvironment and mutation pattern remodeling in lung adenocarcinoma
  publication-title: Genomics
  doi: 10.1016/j.ygeno.2020.12.010
– volume: 12
  start-page: 911906
  year: 2022
  ident: B66
  article-title: Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.911906
– volume: 9
  start-page: e001536
  year: 2021
  ident: B48
  article-title: Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2020-001536
– start-page: 42
  year: 2022
  ident: B156
  article-title: Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC
  publication-title: Biosci. Rep.
  doi: 10.1042/BSR20220892
– volume: 5
  start-page: 129
  year: 2022
  ident: B86
  article-title: Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer
  publication-title: Cancer Drug Resist
  doi: 10.20517/cdr.2021.102
– volume: 13
  start-page: 11577
  year: 2022
  ident: B182
  article-title: UBE3A deletion enhances the efficiency of immunotherapy in non-small-cell lung cancer
  publication-title: Bioengineered
  doi: 10.1080/21655979.2022.2069328
– volume: 13
  start-page: 17588359211006947
  year: 2021
  ident: B56
  article-title: Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients
  publication-title: Ther. Adv. Med. Oncol.
  doi: 10.1177/17588359211006947
– volume: 41
  start-page: 347
  year: 2022
  ident: B12
  article-title: The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
  publication-title: Cancer Metastasis Rev.
  doi: 10.1007/s10555-022-10039-1
– volume: 78
  start-page: 7
  year: 2018
  ident: B35
  article-title: KRAS oncogenic signaling extends beyond cancer cells to orchestrate the microenvironment
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-17-2084
– volume: 36
  start-page: e24636
  year: 2022
  ident: B169
  article-title: A novel algorithm for lung adenocarcinoma based on N6 methyladenosine-related immune long noncoding RNAs as a reliable biomarker for predicting survival outcomes and selecting sensitive anti-tumor therapies
  publication-title: J. Clin. Lab. Anal.
  doi: 10.1002/jcla.24636
– volume: 13
  start-page: 922301
  year: 2022
  ident: B73
  article-title: Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2022.922301
– volume: 13
  start-page: 607
  year: 2022
  ident: B74
  article-title: Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC)
  publication-title: Cell Death Dis.
  doi: 10.1038/s41419-022-05057-4
– volume: 42
  start-page: 828
  year: 2022
  ident: B97
  article-title: KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer
  publication-title: Cancer Commun. (Lond)
  doi: 10.1002/cac2.12327
– volume: 13
  start-page: 276
  year: 2022
  ident: B117
  article-title: New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2
  publication-title: World J. Clin. Oncol.
  doi: 10.5306/wjco.v13.i4.276
– volume: 44
  start-page: 1075
  year: 1998
  ident: B138
  article-title: A novel tumor necrosis factor-alpha mutant with significantly enhanced cytotoxicity and receptor binding affinity
  publication-title: Biochem. Mol. Biol. Int.
  doi: 10.1080/15216549800202142
– volume: 39
  start-page: 239
  year: 2022
  ident: B41
  article-title: Reprogramming the tumor microenvironment to improve the efficacy of cancer immunotherapies
  publication-title: Med. Oncol.
  doi: 10.1007/s12032-022-01842-5
– volume: 21
  start-page: 110
  year: 2022
  ident: B181
  article-title: The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-022-01586-w
– volume: 8
  start-page: 822
  year: 2018
  ident: B141
  article-title: STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-18-0099
– volume: 134
  start-page: 245
  year: 2019
  ident: B2
  article-title: First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2019.06.007
– volume: 17
  start-page: 1481
  year: 2020
  ident: B61
  article-title: Ambient PM2.5 and annual lung cancer incidence: A nationwide study in 295 Chinese counties
  publication-title: Int. J. Environ. Res. Public Health
  doi: 10.3390/ijerph17051481
– volume: 12
  start-page: 962947
  year: 2022
  ident: B108
  article-title: Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.962947
– volume: 12
  start-page: 799455
  year: 2021
  ident: B53
  article-title: Therapeutic implications of tumor microenvironment in lung cancer: Focus on immune checkpoint blockade
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.799455
– volume: 27
  start-page: 30
  year: 2020
  ident: B129
  article-title: Prognostic significance of PAK family kinases in acute myeloid leukemia
  publication-title: Cancer Gene Ther.
  doi: 10.1038/s41417-019-0090-1
– volume: 9
  start-page: 254
  year: 2019
  ident: B16
  article-title: Multigene mutation profiling and clinical characteristics of small-cell lung cancer in never-smokers vs. Heavy smokers (Geno1.3-CLICaP)
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2019.00254
– volume: 10
  start-page: eaaf8223
  year: 2017
  ident: B47
  article-title: Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in non-small cell lung cancer
  publication-title: Sci. Signal
  doi: 10.1126/scisignal.aaf8223
– volume: 14
  start-page: 4239
  year: 2021
  ident: B172
  article-title: ILT4 in colorectal cancer cells induces suppressive T cell contexture and disease progression
  publication-title: Onco Targets Ther.
  doi: 10.2147/OTT.S290348
– volume: 150
  start-page: 112963
  year: 2022
  ident: B39
  article-title: Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2022.112963
– volume: 2022
  start-page: 9139823
  year: 2022
  ident: B183
  article-title: Comprehensive analysis of immune cell infiltration of m6a-related lncRNA in lung squamous cell carcinoma and construction of relevant prognostic models
  publication-title: Biomed. Res. Int.
  doi: 10.1155/2022/9139823
– volume: 110
  start-page: 1665
  year: 2019
  ident: B63
  article-title: Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells
  publication-title: Cancer Sci.
  doi: 10.1111/cas.13989
– volume: 27
  start-page: 289
  year: 2022
  ident: B10
  article-title: Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer
  publication-title: Expert Opin. Emerg. Drugs
  doi: 10.1080/14728214.2022.2113377
– volume: 34
  start-page: 89
  year: 2022
  ident: B123
  article-title: Novel immunotherapeutic drugs for the treatment of lung cancer
  publication-title: Curr. Opin. Oncol.
  doi: 10.1097/CCO.0000000000000800
– volume: 127
  start-page: 59
  year: 2019
  ident: B135
  article-title: Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2018.11.025
– volume: 20
  start-page: 3821
  year: 2019
  ident: B70
  article-title: Epidermal growth factor receptor (EGFR) pathway, yes-associated protein (YAP) and the regulation of programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC)
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms20153821
– volume: 102
  start-page: 914
  year: 2022
  ident: B102
  article-title: Effect of FBXW7 gene mutation on the prognosis of immunotherapy in patients with non-small cell lung cancer
  publication-title: Zhonghua Yi Xue Za Zhi
  doi: 10.3760/cma.j.cn112137-20211021-02332
– volume: 12
  start-page: 667875
  year: 2021
  ident: B94
  article-title: TNF-alpha pathway alternation predicts survival of immune checkpoint inhibitors in non-small cell lung cancer
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.667875
– volume: 16
  start-page: 203
  year: 2016
  ident: B67
  article-title: Over expression of p21-activated kinase 7 associates with lymph node metastasis in esophageal squamous cell cancers
  publication-title: Cancer Biomark.
  doi: 10.3233/CBM-150557
– volume: 118
  start-page: 62
  year: 2018
  ident: B136
  article-title: Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2018.02.005
– volume: 44
  start-page: 750
  year: 2022
  ident: B7
  article-title: Single circulating-tumor-cell-targeted sequencing to identify somatic variants in liquid biopsies in non-small-cell lung cancer patients
  publication-title: Curr. Issues Mol. Biol.
  doi: 10.3390/cimb44020052
– volume: 12
  start-page: 2108
  year: 2020
  ident: B119
  article-title: The HECT E3 ligase e6ap/ube3a as a therapeutic target in cancer and neurological disorders
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers12082108
– volume: 60
  start-page: 102990
  year: 2020
  ident: B144
  article-title: Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2020.102990
– volume: 41
  start-page: 711
  year: 2019
  ident: B3
  article-title: KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2019.02.049
– volume: 9
  start-page: 245
  year: 2022
  ident: B155
  article-title: The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC
  publication-title: Genes Dis.
  doi: 10.1016/j.gendis.2020.04.001
– volume: 110
  start-page: 39
  year: 2018
  ident: B110
  article-title: The 2015 world health organization classification of lung tumors: New entities since the 2004 classification
  publication-title: Pathologica
– volume: 11
  start-page: 630672
  year: 2021
  ident: B152
  article-title: Circulating tumor cell and metabolites as novel biomarkers for early-stage lung cancer diagnosis
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2021.630672
– volume: 29
  start-page: 83
  year: 2022
  ident: B147
  article-title: Tumor microenvironment: Barrier or opportunity towards effective cancer therapy
  publication-title: J. Biomed. Sci.
  doi: 10.1186/s12929-022-00866-3
– volume: 12
  start-page: 951864
  year: 2022
  ident: B192
  article-title: Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.951864
– volume: 19
  start-page: 17010
  year: 2022
  ident: B43
  article-title: Systematic review of smoking cessation inventions for smokers diagnosed with cancer
  publication-title: Int. J. Environ. Res. Public Health
  doi: 10.3390/ijerph192417010
– volume: 71
  start-page: 209
  year: 2021
  ident: B145
  article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21660
– volume: 14
  start-page: 4863
  year: 2022
  ident: B137
  article-title: BRAF inhibitors in non-small cell lung cancer
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers14194863
– volume: 12
  start-page: 2104
  year: 2022
  ident: B146
  article-title: Potential role of tumor-derived exosomes in non-small-cell lung cancer in the era of immunotherapy
  publication-title: Life (Basel)
  doi: 10.3390/life12122104
– volume: 13
  start-page: 4037
  year: 2021
  ident: B4
  article-title: Natural killer cells and dendritic cells: Expanding clinical relevance in the non-small cell lung cancer (NSCLC) tumor microenvironment
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers13164037
– volume: 70
  start-page: 460
  year: 2020
  ident: B149
  article-title: Outdoor air pollution and cancer: An overview of the current evidence and public health recommendations
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21632
– volume: 12
  start-page: 883
  year: 2018
  ident: B164
  article-title: FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
  publication-title: Mol. Oncol.
  doi: 10.1002/1878-0261.12200
– volume: 140
  start-page: 47
  year: 2021
  ident: B76
  article-title: Cancer-associated fibroblasts-derived exosomes promote lung cancer progression by OIP5-AS1/miR-142-5p/PD-L1 axis
  publication-title: Mol. Immunol.
  doi: 10.1016/j.molimm.2021.10.002
– volume: 9
  start-page: 78
  year: 2019
  ident: B193
  article-title: Development and validation of a prognostic signature for malignant pleural mesothelioma
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2019.00078
– volume: 27
  start-page: S78
  year: 2020
  ident: B32
  article-title: Immuno-oncology-the new paradigm of lung cancer treatment
  publication-title: Curr. Oncol.
  doi: 10.3747/co.27.5183
– volume: 2
  start-page: 377
  year: 2021
  ident: B122
  article-title: Overcoming therapy resistance in EGFR-mutant lung cancer
  publication-title: Nat. Cancer
  doi: 10.1038/s43018-021-00195-8
– volume: 13
  start-page: 3410
  year: 2021
  ident: B140
  article-title: Hedgehog/GLI signaling pathway: Transduction, regulation, and implications for disease
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers13143410
– volume: 13
  start-page: 72
  year: 2023
  ident: B166
  article-title: Prognostic biomarkers correlated with immune infiltration in non-small cell lung cancer
  publication-title: FEBS Open Bio
  doi: 10.1002/2211-5463.13501
– volume: 12
  start-page: 1070243
  year: 2022
  ident: B40
  article-title: The prospect of tumor microenvironment-modulating therapeutical strategies
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.1070243
– volume: 34
  start-page: 23
  year: 2022
  ident: B6
  article-title: The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt
  publication-title: J. Egypt Natl. Canc Inst.
  doi: 10.1186/s43046-022-00121-8
– volume: 22
  start-page: 4585
  year: 2016
  ident: B45
  article-title: EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-15-3101
– volume: 280
  start-page: 46
  year: 2013
  ident: B57
  article-title: A role for p21-activated kinase 7 in the development of gastric cancer
  publication-title: FEBS J.
  doi: 10.1111/febs.12048
– volume: 20
  start-page: 662
  year: 2022
  ident: B1
  article-title: Ongoing progress in BRAF-mutated non-small cell lung cancer
  publication-title: Clin. Adv. Hematol. Oncol.
– volume: 12
  start-page: 948405
  year: 2022
  ident: B113
  article-title: Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.948405
– volume: 125
  start-page: 86
  year: 2018
  ident: B101
  article-title: Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2018.09.010
– volume: 83
  start-page: 303
  year: 2022
  ident: B165
  article-title: Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2020.11.004
– volume: 24
  start-page: 343
  year: 2022
  ident: B15
  article-title: The tumor microenvironment reprograms immune cells
  publication-title: Cell Reprogr.
  doi: 10.1089/cell.2022.0047
– volume: 8
  start-page: 359
  year: 2022
  ident: B71
  article-title: LncRNA in tumorigenesis of non-small-cell lung cancer: From bench to bedside
  publication-title: Cell Death Discov.
  doi: 10.1038/s41420-022-01157-4
– volume: 2021
  start-page: 3609028
  year: 2021
  ident: B79
  article-title: Genetic mutation analysis in small cell lung cancer by a novel NGS-based targeted resequencing gene panel and relation with clinical features
  publication-title: Biomed. Res. Int.
  doi: 10.1155/2021/3609028
– volume: 72
  start-page: 7
  year: 2022
  ident: B139
  article-title: Cancer statistics, 2022
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21708
– volume: 4
  start-page: 9918
  year: 2015
  ident: B105
  article-title: Recombinant mutated human TNF in combination with chemotherapy for stage IIIB/IV non-small cell lung cancer: A randomized, phase III study
  publication-title: Sci. Rep.
  doi: 10.1038/srep09918
– volume: 470
  start-page: 95
  year: 2020
  ident: B96
  article-title: The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2019.10.027
– volume: 13
  start-page: 839957
  year: 2022
  ident: B184
  article-title: N 6 -Methyladenosine-Related long non-coding RNAs are identified as a potential prognostic biomarker for lung squamous cell carcinoma and validated by real-time PCR
  publication-title: Front. Genet.
  doi: 10.3389/fgene.2022.839957
SSID ssj0000399364
Score 2.3860745
SecondaryResourceType review_article
Snippet Lung cancer is the common malignant tumor with the highest mortality rate. Lung cancer patients have achieved benefits from immunotherapy, including immune...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1132158
SubjectTerms immunotherapy
PD-1
PD-L1
Pharmacology
resistance
time
TME
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYQJy6opdCm0GoqVVxKtHbivI4tLUIVoD0sEjfLdsZiVUjQPg78-84kYdmtqvbCJYdkoliez_Nwxt8I8ZkgYKV0Way887HWQcaEEoyxVrLyJa0oxxv6l1f5-bX-eZPdrLX64pqwnh64n7gRJQRB-dzx7y8t68IVmUVbalvUmULt2PqSz1tLpjobzH431_0pGcrCqlF4uLXM_5mk3MaEHF254Yk6wv6_RZl_FkuueZ-zV2J3CBvhaz_c12ILmz1xPO55px9PYPJ8jGp-AscwfmakfnwjZpOu3pu8FEz5PAgC79cDb7_OoQ2wWN63M7jn2ry1g2-waIELPAmTCJSVc6RJEOHb4--xGtHlQoEjb_jL1gjTBu7IcoBnodm-uD77MTk9j4dmC7HXeckt6es6qbVPJAabyUB2p_A2CakKSiKzCKJOtUSyCRyUZIrm37qKlMBRX6nTA7HdtA2-E4CFrpxLCuUC6jq3laaoTFUkjVg5iZFQTxNv_MBEzg0x7gxlJKws0ynLsLLMoKxIfFm989DzcPxT-hvrcyXJHNrdDUKWGZBl_oesSHx6QoOhNceKsQ22y7nh7iQF5bk6j8TbHh2rT6V51-Qwi0SxgZuNsWw-aaa3Ha93RbkdBcDvX2Lwh2KHJ4Try1V2JLYXsyV-oPBp4T52K-U36hMZsw
  priority: 102
  providerName: Directory of Open Access Journals
Title Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/36874015
https://www.proquest.com/docview/2783791746
https://pubmed.ncbi.nlm.nih.gov/PMC9974851
https://doaj.org/article/289f1c6b014540d7b75aea84a7d51e4b
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9NAEF6VcuGCeGMe1SKhXqjprr1-HRDiVVWIohwSqbfV7nq2jUjt4iQS-ffMrJ20QQWJSyQ76yT2zOz3zWb2G8ZeowsYIWwWS2ddrJQXMXoJxFBLUbkSI8rSgv7J9_x4or6eZqc7bN3uaHiA8xtTO-onNelmb3_9XL3HgH9HGSfi7aG_PDck7Zmk1KEEMay8xW4jMhXU0eBkoPthZiY0DopSEoE2rhDc-n00f_mYLawKkv438dA_yymv4dPRPXZ3IJb8Q-8J99kONA_Y_qhXpl4d8PHVRqv5Ad_noyvN6tVD1o1DRTjiGJ_SjhHgtKLPaYF2zlvPF8uLtuMXVL13bWscX7ScSkDRa4Fj3k5cFJ2ITo8-x_IQX75JbhEvf5ga-LThM5xbuKNB3SM2Ofoy_nQcD-0YYqfykprW13VSK5cI8CYTHmemwpnEp9JLAaQzCCpVAnDWINqSyaLOjK1qjHrkhaVKH7Pdpm3gKeNQqMrapJDWg6pzUynkbbLC0QCVFRAxuX7w2g1a5dQyY6YxZyFj6WAsTcbSg7Ei9mZzzWWv1PHP0R_JnpuRpLIdTrTdmR6CVmMy6qXLLf31qkRd2CIzYEpl8M4kKBuxV2tv0BiVZBjTQLuca-pfUmAmrPKIPem9Y_NVaR7aIGYRK7b8Zuu3bL_TTM-D8neF2R9S5Gf_davP2R06pFJzmb1gu4tuCS-RSS3sXliB2AtB8hsjTRxw
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeting+immune+cell+types+of+tumor+microenvironment+to+overcome+resistance+to+PD-1%2FPD-L1+blockade+in+lung+cancer&rft.jtitle=Frontiers+in+pharmacology&rft.au=Wang%2C+Man&rft.au=Zhu%2C+Lijie&rft.au=Yang%2C+Xiaoxu&rft.au=Li%2C+Jiahui&rft.date=2023-02-15&rft.issn=1663-9812&rft.eissn=1663-9812&rft.volume=14&rft_id=info:doi/10.3389%2Ffphar.2023.1132158&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fphar_2023_1132158
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon